GO
Loading...

Acorda CEO Projects $255 Million From AMPYRA

Tuesday, 19 Jun 2012 | 6:45 PM ET

Ron Cohen, Acorda Therapeutics president & CEO, offers insight on just how much potential his company's multiple sclerosis drug "AMPYRA" has in the pharmaceutical market.